We have recently demonstrated the antiarrhythmic effects of inhibiting ERO1α, an oxidoreductase downstream of PERK and CHOP in a model of cardiac hypertrophy (Hamilton et al., 2022). Here, EIF2AK3 is linked to cardiac hypertrophy.